ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.
Share | 
| 
| 
|
Dr. Elisabeth Heath, of ZERO Prostate Cancer’s Medical Advisory Board, discusses the recent recognition of apalutamide (Erleada), enzalutamide (Xtandi), and darolutamide (Nubeqa), for use in the treatment of metastatic prostate cancer.
Read the full article from onclive.com
Together, we can END prostate cancer.
Donate Today
